Cite
HARVARD Citation
Schietzel, S. et al. (2022). Impact of the SGLT2 inhibitor empagliflozin on urinary supersaturations in kidney stone formers (SWEETSTONE trial): protocol for a randomised, double-blind, placebo-controlled cross-over trial. BMJ open. 12 (3), p. . [Online].